“After a rigorous review, we concluded that continued investment in Moderna’s H5N1 mRNA vaccine was not scientifically or ethically justifiable,” HHS Communications Director Andrew Nixon told The Defender.
“This is not simply about efficacy — it’s about safety, integrity and trust. The reality is that mRNA technology remains under-tested, and we are not going to spend taxpayer dollars repeating the mistakes of the last administration, which concealed legitimate safety concerns from the public,” Nixon said.
📣 U.S. Cancels Contracts Worth $766 Million for Moderna Bird Flu Vaccine After ‘Rigorous Review’
“After a rigorous review, we concluded that continued investment in Moderna’s H5N1 mRNA vaccine was not scientifically or ethically justifiable,” HHS Communications Director Andrew… pic.twitter.com/TfYJNnFnNM
— Children’s Health Defense (@ChildrensHD) May 30, 2025